Plain-English translation of NCT04613596 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called for people with advanced lung cancer that has a specific genetic change (KRAS G12C mutation). Researchers want to see whether the medication works better when given alone or when combined with , an immunotherapy drug that helps your body fight cancer. The trial has two main parts: Phase 2 tests safety and early effectiveness, while Phase 3 compares the combination treatment directly against alone.
Many people with this type of lung cancer don't have good treatment options, especially in early stages of the disease. This trial is exploring whether targeting the specific genetic mutation with the new treatment—either by itself or combined with immunotherapy—can help more patients live longer and feel better.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will take the medication by mouth twice daily. Depending on which group you're assigned to, you may receive the medication alone or in combination with infusions. You will have regular visits to the clinic for blood tests, imaging scans, and check-ins with your medical team to monitor how well the treatment is working and manage any side effects. The trial involves two phases—an initial testing phase to confirm safety, followed by a larger comparison phase to see which approach works best.
AI-generated summary from trial data · Sep 18, 2026 · Not medical advice
United States